Vaccine Adjuvants Market Size To Reach $1.9 Billion By 2030

Vaccine Adjuvants Market Growth & Trends

The global vaccine adjuvants market is expected to reach USD 1.9 billion by 2030,  according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 2.3% from 2023 to 2030. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

 Request a free sample copy or view report summary: Vaccine Adjuvants Market Report

Vaccine Adjuvants Market Report Highlights

• The vaccine adjuvants market is segmented based on type into an adjuvant emulsion, pathogen, particulate, combination, and others. The particulate segment held the largest market share in 2022.

• The infectious diseases segment accounted for the largest revenue share of 68.1% in 2022. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others.

• The administration segment is categorized into oral, intradermal, intranasal, intramuscular, and others. Due to better immune specificity, the intramuscular segment accounted for the largest revenue share of 33.8% in 2022

• North America dominated the market and accounted for the largest revenue share of 41.7% in 2022. The factors contributing to the growth of the market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases.

Vaccine Adjuvants Market Segmentation

Grand View Research has segmented the global vaccine adjuvants market on the basis of type, application, route of administration, and region:

Vaccine Adjuvants Type Outlook (Revenue, USD Million, 2018 - 2030)

• Pathogen

• Adjuvant emulsion

• Particulate

• Combination

• Others                                             

Vaccine Adjuvants Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious diseases

• Cancer

• Others

Vaccine Adjuvants Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Intradermal

• Intranasal

• Intramuscular

• Others

Vaccine Adjuvants Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Vaccine Adjuvants Market

• GlaxoSmithKline plc.

• Novavax, Inc.

• Adjuvance Technologies, Inc.

• SPI Pharma

• Agenus, Inc.

• CSL Limited

• InvivoGen

• Brenntag Biosector